Aerie's Roclatan meets in second Phase III for IOP

By Chris Lieu | Jun 2, 2017 | 3:01 PM GMT

Aerie Pharmaceuticals Inc. (NASDAQ:AERI) reported top-line data from the Phase III Mercury 2 trial in 750 patients with open-angle glaucoma or ocular hypertension with a baseline intraocular pressure (IOP) of >20 to <36 mmHg showing that